Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products' fair market prices.
Centers for Medicare & Medicaid Services (CMS) will begin negotiating with manufacturers on the price of Medicare Part D drugs beginning this year. In September, CMS will publish the list of 10 Part D selected drugs for negotiations. A key issue in the negotiations will be determination of the fair market price for a product.
Key Topics Include:
- Outline how CMS might select the 10 products that will be required to negotiate their prices this fall
- Describe how CMS will determine fair market prices for Medicare Part D drugs
- Suggest actions that manufacturers could take in response to the Medicare Part D price negotiation requirements
Presenters
Director, Client Engagement
Pricing, Market Access and Reimbursement
ICON
Mark McCoy has over 25 years of experience in US and global pharmaceutical marketing and specializes in market access communications. His extensive experience includes developing and communicating powerful value propositions for prelaunch and launch brands in a broad range of therapeutic categories.
Divisional Principal
Market Access
ICON
Earlene Biggs has over 20 years of experience delivering insights and strategies optimizing access and stakeholder engagement for pharmaceutical and biotech companies across the product lifecycle. In the past 5 years she has led her teams to successfully deliver 200+ research and analytics engagements with ICON clients.
Head of Business Intelligence
Commercial Solutions
ICON
Bruce Capobianco has supported business technology for over 20 years. He is a thought partner and trusted business advisor to clinical and commercial businesses by contributing to innovative and efficient study designs through robust evidence generation. Bruce is an evangelist in developing and driving adoption to AI to accelerate research.
Lead Consultant
Global Health Economics and Outcomes Research
ICON
Benjamin Cieply is an experienced consultant with ICON’s Global Health Economics and Outcomes Research team. He has been largely focused on drugs in development, aiming to help clients understand their asset’s value and price potential and the evidence needed to support this.
VP, Scientific Affairs
Oncology Medical Strategy
ICON
Tanja Obradovic's experience includes 20+ years in clinical research as well as medical strategy leadership of oncology immunotherapy drug treatment value and reimbursement policy including packages for major private and public insurers and regulatory bodies such as CMS and NICE.
VP, PMAC Consulting
Patient Insight, Market Access and Commercial
ICON
Ki Park leads a team of principal SMEs with expertise in advanced analytics in the areas of payer, patient, promotional effectiveness, and commercial strategy. His 15 years at Symphony Health has focused on healthcare claims informatics specializing in payer and patient analytics.
Senior Principal
Global Health Economics and Outcomes Research
ICON
Nancy Risebrough is a Senior Principal within Global Health Economics and Outcomes Research at ICON. She has more than 20 years of experience working in decision analytic-modeling, health technology assessment (HTA), burden of illness studies, and reimbursement strategy and HTA submissions. Areas of therapeutic expertise include oncology, COPD, asthma, diabetes, and blood disorders.
Production Partner
ICON
ICON is a global provider of consulting, and outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We focus our innovation on the factors that are critical to our clients - reducing time to market, reducing cost and increasing quality.
Additional Content From ICON
Social Media Data: Opportunities and Insights for Clinical Research
Hear four experts from ICON and Kap Code provide insights on how to collect, use, analyze, and interpret social media data in different contexts. These experts share knowledge from over fifteen years of successfully developing and adapting algorithms to treat this kind of data.
An Introduction to Infectious Disease Modeling
Hear ICON experts give an in-depth overview of infectious disease modeling with a focus on assessment of interventions and its challenges.
Evidence Synthesis for Sparse Evidence Base, Heterogeneous Studies, and Disconnected Networks
Standard models in evidence synthesis work well in settings characterized by a large evidence base, the absence of effect modifiers, and connected networks. Handling sparse data, substantial between-study heterogeneity and disconnected studies, however, poses challenges to researchers and requires advanced methodology.
Additional Content From HealthEconomics.Com
Finding Value in Linking Real-World Data with Social Determinants of Health
Hear Pamela Landsman-Blumberg and Rick Chapman highlight the importance of SDOH and discuss examples of how claims data and EMR linked with SDOH can inform use cases.
What Every Researcher Needs to Know About Using Medicare Data for Real World Evidence
Join three panelists who will provide a practical overview of how and why to use data from Medicare for real world studies.
Economic Impact of Representativeness in Clinical Trials: How Real-World Data Can Help
This panel of real-world evidence (RWE) experts explore the economic impact and role of RWE in improving representativeness of research.
Related Content
Finding Value in Linking Real-World Data with Social Determinants of Health
Hear Pamela Landsman-Blumberg and Rick Chapman highlight the importance of SDOH and discuss examples of how claims data and EMR linked with SDOH can inform use cases.
What Every Researcher Needs to Know About Using Medicare Data for Real World Evidence
Join three panelists who will provide a practical overview of how and why to use data from Medicare for real world studies.
Stay Ahead of the Game: Learn How to Conduct an Evidence-Based GVD Faster and Smarter to Improve Market Access
Hear several experts address systematic literature review issues that can negatively affect your Global Value Dossiers (GVDs) and how automation can improve your product's market access.